SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 628.00-2.2%Nov 4 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: CuttingEdge Bio who wrote (3445)2/13/2022 10:59:00 PM
From: Miljenko Zuanic1 Recommendation

Recommended By
CuttingEdge Bio

   of 3557
 
<The VEGF arm of the bispecific is at a higher molar dose than Lucentis is at its dosage.>
Yes it is, and you think none tried 75 or 100 mcL for lucentis? Like they did for Eylea (4 or 6 mg) and found additional benefit! Or positive for hard to treat at 2 mg!
So, what is molar dose strain for 6 mg vabysmo relative to 0.5 mg Lucentis, accounting potency difference?
6.0/149 (0.04 mcM) versus 0.5/48.4 (0.01 mCM)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News